Shares of Insmed rose about 7% following the release of late-stage clinical data for Arikayce, the company’s treatment for a chronic lung infection. The Phase 3b ENCORE study met both its primary and secondary endpoints, according to analyst reports, with patients showing improved respiratory symptom scores and increased rates of culture conversion compared with control.
Analysts at Morgan Stanley highlighted that the ENCORE findings support using Arikayce beyond the current population of refractory patients. That expansion would raise the potential target pool in the U.S. and Japan from an estimated 30,000 patients to roughly 200,000, the firm said.
Insmed is planning to submit an application for a label expansion in the second half of 2026. Morgan Stanley noted that any meaningful revenue contribution tied to a broader indication is more likely to materialize beginning in 2027. In the near term, Morgan Stanley added that investor focus is expected to remain concentrated on the commercial launch of Insmed’s other product, Brinsupri.
Wolfe Research also interpreted the ENCORE results favorably, pointing to sustained clinical benefits and a safety profile consistent with prior trials. Wolfe noted that improvements in symptom scores persisted through 15 months and that culture conversion occurred earlier and was maintained for a longer period among treated patients.
Both Morgan Stanley and Wolfe Research flagged a higher incidence of adverse events in the Arikayce arm relative to the control arm, but characterized those events as consistent with previously observed side effects. Analysts also observed lower discontinuation rates compared with earlier studies, which they attributed to increased familiarity with the therapy by both patients and prescribing physicians.
Analysts said that an expanded label could materially enhance long-term growth prospects for Insmed. However, they cautioned that short-term movements in the stock may depend on other catalysts, including readouts from the company’s additional development programs. Wolfe Research specifically suggested investor attention may revert to Brinsupri, forecasting revenue for that product ahead of consensus and projecting that commercial momentum could build in the second half of the year, supporting earnings expansion and a potential move toward profitability.
Clear summary: Positive Phase 3b ENCORE data for Arikayce drove a roughly 7% rise in Insmed’s shares. The results support a planned label expansion filing in H2 2026 that could expand the target patient population in the U.S. and Japan from about 30,000 to roughly 200,000, with significant revenue impact likely from 2027. Near-term investor focus remains on the launch and revenue trajectory of Brinsupri.